Treatments

Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal

Yuvraj — Thu, 30 Apr 2026 09:45:39 +0000

Teva Pharmaceuticals has entered into a definitive agreement to acquire Emalex Biosciences, strengthening its neuroscience pipeline through the addition of ecopipam, a late-stage investigational treatment for pediatric Tourette syndrome. The move reinforces the company’s strategic shift toward innovation-led expansion, with ecopipam positioned as a registration-ready, first-in-class selective dopamine D1 receptor antagonist. The asset has already […]

The post Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal first appeared on World Pharma Today.

Weight-Loss Pills Mark a Turning Point for Pharma Industry

Yuvraj — Mon, 16 Feb 2026 11:58:02 +0000

The global pharmaceutical industry is entering a pivotal phase in obesity therapeutics as companies accelerate the transition from injectable GLP-1 drugs to oral weight-loss treatments, a shift expected to significantly expand patient access, alter reimbursement dynamics, and intensify competitive pressures in one of the fastest-growing drug categories. The commercial success of GLP-1 receptor agonists such […]

The post Weight-Loss Pills Mark a Turning Point for Pharma Industry first appeared on World Pharma Today.

Future Trends in Pharmaceutical Drug Delivery Platforms

Yuvraj — Fri, 06 Feb 2026 11:46:15 +0000

Forward-looking perspective on the convergence of digital technology, bioengineering, and material science in creating the next generation of therapeutic delivery systems.

The post Future Trends in Pharmaceutical Drug Delivery Platforms first appeared on World Pharma Today.

Drug Delivery Innovations Supporting Personalized Medicine

Yuvraj — Fri, 06 Feb 2026 11:26:36 +0000

Investigation into the technological advancements that enable individualized therapeutic regimens, focusing on precision dosing, genetic tailoring, and smart delivery systems.

The post Drug Delivery Innovations Supporting Personalized Medicine first appeared on World Pharma Today.

Nanotechnology Applications in Drug Delivery Development

Yuvraj — Fri, 06 Feb 2026 10:30:02 +0000

Investigation into the role of nanoscale carriers in enhancing therapeutic precision, overcoming biological barriers, and enabling the delivery of sensitive genetic materials.

The post Nanotechnology Applications in Drug Delivery Development first appeared on World Pharma Today.

Daiichi Eyes Commercialization of its Leukemia Med Vanflyta

Yuvraj — Sat, 10 Jan 2026 08:44:28 +0000

Daiichi Sankyo is now looking out for new horizons when it comes to its leukemia med Vanflyta, with Genesis Pharma signing to commercialize the drug across certain European countries. This exclusive license, as well as the supply agreement goes on to cover 13 Central and Eastern European markets such as Bulgaria, the Czech Republic, Estonia, Hungary, […]

The post Daiichi Eyes Commercialization of its Leukemia Med Vanflyta first appeared on World Pharma Today.

Nimbus, Lilly Ink Licence Agreement on Treatments in Obesity

Yuvraj — Sat, 10 Jan 2026 07:41:36 +0000

Nimbus Therapeutics has announced that it has entered into a multi-year research partnership and a $1.3 billion exclusive license agreement with Eli Lilly in order to develop oral treatments in obesity as well as other metabolic diseases. Lilly, which very recently went ahead and announced the topline results coming from its phase III trial studying Orforglipron, […]

The post Nimbus, Lilly Ink Licence Agreement on Treatments in Obesity first appeared on World Pharma Today.

UK Plans to Produce Cancer Treatment from Nuclear Waste

Yuvraj — Fri, 19 Dec 2025 11:39:31 +0000

Bicycle Therapeutics has entered into a 15-year agreement with the UK Nuclear Decommissioning Authority (NDA) to utilize reprocessed uranium from nuclear reactors for the production of precision cancer therapies. Under the terms of the deal, announced by the UK government, the NDA will provide the biotech company with access to up to 400 tonnes of […]

The post UK Plans to Produce Cancer Treatment from Nuclear Waste first appeared on World Pharma Today.

Regeneron Looks to Infusing More Funds into Gene Editing

Yuvraj — Fri, 05 Dec 2025 07:32:44 +0000

Regeneron Pharmaceuticals is going ahead and investing more funds into gene editing, as it has announced a collaboration with Tessera Therapeutics in December 2025, so as to create an experimental program pertaining to rare liver and lung disease. At the core of this deal is a treatment that Tessera, a well-funded startup that is backed […]

The post Regeneron Looks to Infusing More Funds into Gene Editing first appeared on World Pharma Today.

FDA Looks to Accelerate Biosimilar Drug Development

Yuvraj — Tue, 25 Nov 2025 13:33:37 +0000

The FDA has gone on to propose certain new policies in order to accelerate biosimilar drug development and at the same time also lower the cost pertaining to biosimilar agents when it comes to cancer as well as any other serious illnesses. These policies go on to include major updates so as to simplify the biosimilarity […]

The post FDA Looks to Accelerate Biosimilar Drug Development first appeared on World Pharma Today.